Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Trial Profile

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 30 Jun 2022 Planned End Date changed from 15 Mar 2022 to 15 Jul 2022.
    • 07 Jun 2022 Results of pooled analysis from NCT03838367, NCT04313075, NCT04504942; exploring the effect of leronlimab on circulating tumor associated cells (TACs) from peripheral blood as a surrogate and early predictor of drug response, presented at the 58th Annual Meeting of the American Society of Clinical Oncolog
    • 13 Apr 2022 Blood sample from 3 studies (NCT03838367, NCT04313075 & NCT04504942) were used to assess the predictive value of TACs, measured by the LifeTracDx assay, presented at the 113th Annual Meeting of the American Association for Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top